Methodologic issues concerning stachyhemolysin and stachyrase-A as clinical biomarkers.
Page-EH; Biagini-RE; Beezhold-DH
Med Sci Monit 2005 Sep; 11(9):LE7-LE8
We are writing about the recently published article "Antibodies against Stachybotrys chartarum extract and its antigenic components, Stachyhemolysin and Stachyrase-A: a new clinical biomarker" . The author states that his hypothesis is "that environmental exposure to Stachyhemolysin and Stachyrase-A may result in antibody production against these mold antigens." There are numerous methodologic defi ciencies in this paper which preclude drawing any conclusions regarding the utility of anti-stachyhemolsyin and anti-stachyrase-A antibodies as biomarkers. In closing, we feel there are signifi cant problems with this paper which preclude the author's conclusions that antibodies to Stachyhemolysin and Stachyrase-A are new clinical biomarkers of exposure to Stachybotrys chartarum. The fi ndings and conclusions in this letter to the editor are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health.
Biomarkers; Environmental-exposure; Antibody-response; Exposure-levels; Exposure-assessment; Exposure-limits
DSHEFS; DART; HELD
Medical Science Monitor